Why the study?
Does rivaroxaban prevent major ischemic or hemorrhagic events compared to apixaban in Medicare beneficiaries 65 years or older with atrial fibrillation?
Does rivaroxaban prevent major ischemic or hemorrhagic events compared to apixaban in Medicare beneficiaries 65 years or older with atrial fibrillation?
In older Medicare patients with atrial fibrillation, rivaroxaban is associated with a higher risk of major ischemic or hemorrhagic events compared to apixaban.
Answers are grounded in this paper and cite their sources.
May support preferring apixaban over rivaroxaban in older AF patients; leaves open need for randomized confirmation.
Among Medicare beneficiaries 65 years or older with atrial fibrillation, treatment with rivaroxaban compared with apixaban was associated with a significantly increased risk of major ischemic or hemorrhagic events.
No takes yet. Share an insight, caveat, or question.
Ray et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: